TY - T1的种族/民族差异脑出血复发的风险(S15.005) JF -神经学乔-神经学六世- 92 - 15补充SP - S15.005盟奥黛丽现有非盟-扎卡里·王盟-维克多Torres-Lopez AU -桑首页托什没吃非盟- Hooman Kamel盟Ashkan Shoamanesh AU -鲁斯塔姆Al-Shahi萨尔曼AU -乔纳森Rosand盟温迪Ziai AU -丹尼尔·汉利盟-丹尼尔·吴盟-查尔斯Matouk AU -劳伦无盟圭多要求非盟-凯文Sheth Y1 - 2019/04/09 UR - //www.ez-admanager.com/content/92/15_Supplement/S15.005.abstract N2 -目的:确定自发性脑出血的风险(我)复发和确定复发的相关因素在一个大的种族和种族多元化的人口。背景:种族与第一次我的风险有关,但是种族/民族的影响我复发的风险还没有被很好地研究了在一个大的,多样化的人口。设计/方法:我们使用索赔数据之间的所有非联邦加州急症护理医院住院1月1日,2005年和2011年12月31日为我确定病人住院。加州居民生存排放都包括在内。我们使用验证诊断码来标识我复发的主要结果。然后我们生存曲线和log-rank测试用于未经调整的分析跨种族/民族的生存和多变量Cox比例风险回归确定与我复发的风险相关的因素在调整了潜在的混杂因素。结果:我们发现31554加州居民最早我那些幸存下来的排放,其中15828(50%)是白人,6254(20%)拉美裔,4268亚洲(14%)、2820(9%)的黑人。有1339名复发(4.2%)在平均随访时间2.9年(IQR 3.8)。1年复发率为3.0%(95%可信区间2.8% - -3.2%)。在多变量分析中,黑人(HR 1.22, 95%可信区间1.01 - -1.48;p = 0.04)和亚洲(HR 1.29, 95%可信区间1.10 - -1.50;p = 0.001)有较高的风险比白人我复发(参考类别)。 Private insurance was associated with a significant reduction in the risk of ICH recurrence compared to subjects with Medicare (HR 0.60, 95% CI 0.50–0.73, p<0.001), with consistent estimates across racial/ethnic groups.Conclusions: Black and Asian subjects had a higher risk of ICH recurrence than whites, whereas private insurance was associated with a reduced risk of ICH recurrence compared to subjects with Medicare. Further research is needed to determine drivers of these disparities.Disclosure: Dr. Leasure has nothing to disclose. Dr. King has nothing to disclose. Dr. Torres-Lopez has nothing to disclose. Dr. Murthy has nothing to disclose. Dr. Kamel has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Roivant Sciences, Medtronic, BMS, and Roche Diagnostics Corporation. Dr. Kamel has received personal compensation in an editorial capacity for JAMA Neurology. Dr. Kamel has received research support from NIH/NINDS. Dr. Shoamanesh has nothing to disclose. Dr. Al-Shahi Salman has nothing to disclose. Dr. Rosand has nothing to disclose. Dr. Ziai has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with CR Bard, Inc., Headsense, Inc. Dr. Hanley has nothing to disclose. Dr. Woo has nothing to disclose. Dr. Matouk has nothing to disclose. Dr. Sansing has nothing to disclose. Dr. Falcone has nothing to disclose. Dr. Sheth has received royalty, license fees, or contractual rights payments from Alva Health. Dr. Sheth has received research support from Biogen, Novartis, Bard, and Hyperfine. ER -